

Caroline A Sabin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/82901/publications.pdf>

Version: 2024-02-01

615
papers

42,061
citations

1994

101
h-index

3407

183
g-index

640
all docs

640
docs citations

640
times ranked

25695
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. <i>New England Journal of Medicine</i> , 2003, 349, 1993-2003.	27.0	1,560
2	Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. <i>Lancet, The</i> , 2002, 360, 119-129.	13.7	1,415
3	Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. <i>New England Journal of Medicine</i> , 2007, 356, 1723-1735.	27.0	1,393
4	Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus. <i>Archives of Internal Medicine</i> , 2006, 166, 1632.	3.8	1,004
5	Natural History and Outcome in Systemic AA Amyloidosis. <i>New England Journal of Medicine</i> , 2007, 356, 2361-2371.	27.0	817
6	Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. <i>Lancet, The</i> , 2008, 371, 1417-1426.	13.7	809
7	Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. <i>Aids</i> , 2003, 17, 1179-1193.	2.2	770
8	Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. <i>Lancet, The</i> , 2014, 384, 241-248.	13.7	767
9	Targeting C-reactive protein for the treatment of cardiovascular disease. <i>Nature</i> , 2006, 440, 1217-1221.	27.8	621
10	Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. <i>Journal of Infectious Diseases</i> , 2010, 201, 318-330.	4.0	575
11	Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. <i>Lancet, The</i> , 2000, 355, 2032-2036.	13.7	496
12	Frequency of inherited bleeding disorders in women with menorrhagia. <i>Lancet, The</i> , 1998, 351, 485-489.	13.7	458
13	Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. <i>Aids</i> , 2014, 28, 1193-1202.	2.2	453
14	Incidence and Risk Factors for New-Onset Diabetes in HIV-Infected Patients. <i>Diabetes Care</i> , 2008, 31, 1224-1229.	8.6	448
15	Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. <i>Hepatology</i> , 1998, 27, 1207-1212.	7.3	410
16	Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. <i>Aids</i> , 2010, 24, 1537-1548.	2.2	381
17	Late presentation of HIV infection: a consensus definition. <i>HIV Medicine</i> , 2011, 12, 61-64.	2.2	378
18	Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. <i>Aids</i> , 2007, 21, 983-991.	2.2	374

#	ARTICLE	IF	CITATIONS
19	The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. <i>Aids</i> , 2010, 24, 123-137.	2.2	360
20	Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. <i>Aids</i> , 2003, 17, 1179-93.	2.2	335
21	Lipid Profiles in HIV-Infected Patients Receiving Combination Antiretroviral Therapy: Are Different Antiretroviral Drugs Associated with Different Lipid Profiles?. <i>Journal of Infectious Diseases</i> , 2004, 189, 1056-1074.	4.0	318
22	3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. <i>Lancet, The</i> , 2006, 367, 225-232.	13.7	310
23	Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 491-501.	2.8	309
24	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. <i>Lancet, The</i> , 2004, 364, 51-62.	13.7	303
25	The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. <i>HIV Medicine</i> , 2006, 7, 218-230.	2.2	296
26	Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. <i>BMJ: British Medical Journal</i> , 2011, 343, d6016-d6016.	2.3	282
27	Late Diagnosis of HIV Infection: Epidemiological Features, Consequences and Strategies to Encourage Earlier Testing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, S3-S8.	2.1	274
28	The progression of HCV-associated liver disease in a cohort of haemophilic patients. <i>British Journal of Haematology</i> , 1994, 87, 555-561.	2.5	267
29	Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. <i>Aids</i> , 2007, 21, 1185-1197.	2.2	264
30	Pregnancy in women with von Willebrand's disease or factor XI deficiency. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1998, 105, 314-321.	2.3	258
31	Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). <i>PLoS Medicine</i> , 2013, 10, e1001510.	8.4	256
32	A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. <i>Aids</i> , 2006, 20, 2043-2050.	2.2	233
33	A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. <i>Gastroenterology</i> , 2002, 123, 1013-1019.	1.3	219
34	Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e2095-e2106.	5.8	218
35	von Willebrand disease in women with menorrhagia: a systematic review. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2004, 111, 734-740.	2.3	217
36	All-cause mortality in treated HIV-infected adults with CD4 >=500/mm ³ compared with the general population: evidence from a large European observational cohort collaboration. <i>International Journal of Epidemiology</i> , 2012, 41, 433-445.	1.9	217

#	ARTICLE	IF	CITATIONS
37	Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 565-575.	9.1	217
38	Cardio- and cerebrovascular events in HIV-infected persons. <i>Aids</i> , 2004, 18, 1811-1817.	2.2	210
39	HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. <i>Lancet</i> , The, 2006, 368, 451-458.	13.7	209
40	HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. <i>Aids</i> , 2008, 22, 2143-2153.	2.2	207
41	Insulin Resistance Plays a Significant Role in Liver Fibrosis in Chronic Hepatitis C and in the Response to Antiviral Therapy. <i>American Journal of Gastroenterology</i> , 2005, 100, 1509-1515.	0.4	206
42	When to Initiate Combined Antiretroviral Therapy to Reduce Mortality and AIDS-Defining Illness in HIV-Infected Persons in Developed Countries. <i>Annals of Internal Medicine</i> , 2011, 154, 509.	3.9	205
43	Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. <i>Lancet</i> , The, 2004, 363, 2116-2121.	13.7	201
44	Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. <i>Aids</i> , 2009, 23, 1743-1753.	2.2	200
45	Increased brain-predicted aging in treated HIV disease. <i>Neurology</i> , 2017, 88, 1349-1357.	1.1	200
46	Interrelationships among Quantity of Human Cytomegalovirus (HCMV) DNA in Blood, Donorâ€™Recipient Serostatus, and Administration of Methylprednisolone as Risk Factors for HCMV Disease following Liver Transplantation. <i>Journal of Infectious Diseases</i> , 1997, 176, 1484-1490.	4.0	197
47	Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America. <i>Clinical Infectious Diseases</i> , 2005, 41, 1772-1782.	5.8	197
48	Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. <i>Aids</i> , 2000, 14, 2857-2867.	2.2	194
49	Late presenters in the era of highly active antiretroviral therapy. <i>Aids</i> , 2004, 18, 2145-2151.	2.2	194
50	Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 8309-8314.	7.1	194
51	Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. <i>Aids</i> , 2006, 20, 741-749.	2.2	193
52	The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.2	193
53	Response to combination antiretroviral therapy: variation by age. <i>Aids</i> , 2008, 22, 1463-1473.	2.2	188
54	Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. <i>Aids</i> , 2001, 15, 185-194.	2.2	187

#	ARTICLE	IF	CITATIONS
55	Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis. <i>Clinical and Experimental Immunology</i> , 2008, 88, 243-252.	2.6	185
56	Portal Vein Resection in Borderline Resectable Pancreatic Cancer: A United Kingdom Multicenter Study. <i>Journal of the American College of Surgeons</i> , 2014, 218, 401-411.	0.5	181
57	An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 214-223.	1.8	180
58	Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. <i>Bone Marrow Transplantation</i> , 1998, 21, 597-605.	2.4	171
59	Assessing health-related quality-of-life in individuals with haemophilia. <i>Haemophilia</i> , 1999, 5, 378-385.	2.1	171
60	Increased number of primed activated CD8+CD38+CD45RO+T cells predict the decline of CD4+T cells in HIV-1-infected patients. <i>Aids</i> , 1996, 10, 827-834.	2.2	168
61	The Association between Hepatitis C Virus Genotype and Human Immunodeficiency Virus Disease Progression in a Cohort of Hemophilic Men. <i>Journal of Infectious Diseases</i> , 1997, 175, 164-167.	4.0	167
62	Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. <i>Annals of Neurology</i> , 2008, 63, 213-221.	5.3	167
63	Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. <i>BMJ: British Medical Journal</i> , 2005, 331, 1368.	2.3	163
64	British HIV Association guidelines for the routine investigation and monitoring of adult HIV-infected individuals 2011. <i>HIV Medicine</i> , 2012, 13, 1-44.	2.2	162
65	Nutritional status and prognosis in cirrhotic patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 563-572.	3.7	161
66	Predicting risk of cancer during HIV infection. <i>Aids</i> , 2013, 27, 1433-1441.	2.2	158
67	The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. <i>Gut</i> , 2000, 47, 845-851.	12.1	157
68	Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. <i>Lancet HIV</i> , 2018, 5, e291-e300.	4.7	155
69	Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study*. <i>HIV Medicine</i> , 2011, 12, 412-421.	2.2	154
70	Assessment of menstrual blood loss and gynaecological problems in patients with inherited bleeding disorders. <i>Haemophilia</i> , 1999, 5, 40-48.	2.1	153
71	Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. <i>Aids</i> , 2005, 19, 85-90.	2.2	152
72	British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. <i>HIV Medicine</i> , 2012, 13, 1-6.	2.2	149

#	ARTICLE	IF	CITATIONS
73	Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. <i>Aids</i> , 1997, 11, 889-893.	2.2	146
74	Variations in Coagulation Factors in Women: Effects of Age, Ethnicity, Menstrual Cycle and Combined Oral Contraceptive. <i>Thrombosis and Haemostasis</i> , 1999, 82, 1456-1461.	3.4	142
75	Outcome of orthotopic liver transplantation in patients with haemophilia. <i>Gut</i> , 1998, 42, 744-749.	12.1	140
76	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. <i>Clinical Infectious Diseases</i> , 2014, 58, 1312-1321.	5.8	140
77	Human C-Reactive Protein Increases Cerebral Infarct Size after Middle Cerebral Artery Occlusion in Adult Rats. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2004, 24, 1214-1218.	4.3	137
78	Effect of HIV-1 Subtype on Virologic and Immunologic Response to Starting Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2009, 48, 1296-1305.	5.8	134
79	Determinants of HIV-1 transmission in men who have sex with men: a combined clinical, epidemiological and phylogenetic approach. <i>Aids</i> , 2010, 24, 1739-1747.	2.2	130
80	The Coding Causes of Death in HIV (CoDe) Project. <i>Epidemiology</i> , 2011, 22, 516-523.	2.7	129
81	Factors Influencing Increases in CD4 Cell Counts of HIV-Positive Persons Receiving Long-Term Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2004, 190, 1860-1868.	4.0	127
82	Do people with HIV infection have a normal life expectancy in the era of combination antiretroviral therapy?. <i>BMC Medicine</i> , 2013, 11, 251.	5.5	127
83	PROSPECTIVE STUDY OF HUMAN BETAHERPESVIRUSES AFTER RENAL TRANSPLANTATION. <i>Transplantation</i> , 2000, 69, 2400-2404.	1.0	126
84	The Changing Incidence of AIDS Events in Patients Receiving Highly Active Antiretroviral Therapy. <i>Archives of Internal Medicine</i> , 2005, 165, 416.	3.8	124
85	Newly diagnosed HIV infections: review in UK and Ireland. <i>BMJ: British Medical Journal</i> , 2005, 330, 1301-1302.	2.3	124
86	Serologic Evidence of Human Herpesvirus 8 Transmission by Homosexual but Not Heterosexual Sex. <i>Journal of Infectious Diseases</i> , 1999, 180, 600-606.	4.0	122
87	Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. <i>Aids</i> , 1999, 13, 951-956.	2.2	122
88	Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? <i>Epidemiological and Modeling Insights</i> . <i>Clinical Infectious Diseases</i> , 2016, 62, 1072-1080.	5.8	122
89	Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. <i>HIV Medicine</i> , 2016, 17, 255-268.	2.2	122
90	Proinflammatory Effects of Bacterial Recombinant Human C-Reactive Protein Are Caused by Contamination With Bacterial Products, Not by C-Reactive Protein Itself. <i>Circulation Research</i> , 2005, 97, e97-103.	4.5	121

#	ARTICLE	IF	CITATIONS
91	Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. <i>Aids</i> , 2005, 19, 487-494.	2.2	120
92	Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. <i>HIV Medicine</i> , 2003, 4, 1-10.	2.2	114
93	Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study. <i>BMJ: British Medical Journal</i> , 1997, 314, 329-329.	2.3	114
94	Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. <i>Neurology</i> , 2014, 83, 134-141.	1.1	112
95	Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival. <i>Aids</i> , 1996, 10, 1515-1520.	2.2	111
96	CD8+, CD38+ Lymphocyte Percent. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997, 14, 158-162.	0.3	111
97	Quality of life during menstruation in patients with inherited bleeding disorders. <i>Haemophilia</i> , 1998, 4, 836-841.	2.1	109
98	Virological response to protease inhibitor therapy in an HIV clinic cohort. <i>Aids</i> , 1999, 13, 367-373.	2.2	109
99	No time to wait: how many HIV-infected homosexual men are diagnosed late and consequently die? (England and Wales, 1993-2002). <i>Aids</i> , 2005, 19, 513-520.	2.2	109
100	Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS-Defining Conditions Are Created Equal. <i>Clinical Infectious Diseases</i> , 2009, 48, 1138-1151.	5.8	108
101	Reduced bone mineral density in HIV-positive individuals. <i>Aids</i> , 2001, 15, 1731-1733.	2.2	107
102	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. <i>Clinical Infectious Diseases</i> , 2018, 66, 893-903.	5.8	105
103	Contribution of human leukocyte antigens to the antibody response to hepatitis B vaccination. <i>Tissue Antigens</i> , 1997, 50, 8-14.	1.0	102
104	British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.). <i>HIV Medicine</i> , 2014, 15, 1-6.	2.2	101
105	Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. <i>BMC Medicine</i> , 2016, 14, 61.	5.5	100
106	Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. <i>Aids</i> , 2000, 14, 1163-1170.	2.2	98
107	HBV A₁₇₆₂T, G₁₇₆₄A Mutations Are a Valuable Biomarker for Identifying a Subset of Male HBsAg Carriers at Extremely High Risk of Hepatocellular Carcinoma: A Prospective Study. <i>American Journal of Gastroenterology</i> , 2008, 103, 2254-2262.	0.4	98
108	Impact of HIV on Host-Virus Interactions during Early Hepatitis C Virus Infection. <i>Journal of Infectious Diseases</i> , 2008, 197, 1558-1566.	4.0	98

#	ARTICLE	IF	CITATIONS
109	Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE ^{-/-} mice. <i>Atherosclerosis</i> , 2008, 196, 248-255.	0.8	96
110	Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. <i>Liver Transplantation</i> , 2005, 11, 386-395.	2.4	95
111	Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. <i>Aids</i> , 2002, 16, 53-61.	2.2	93
112	Do people living with HIV experience greater age advancement than their HIV-negative counterparts?. <i>Aids</i> , 2019, 33, 259-268.	2.2	93
113	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥ 200 Cells/ μ L in the Post-Combination Antiretroviral Therapy Era. <i>Clinical Infectious Diseases</i> , 2013, 57, 1038-1047.	5.8	92
114	Single portal pressure measurement predicts survival in cirrhotic patients with recent bleeding. <i>Gut</i> , 1999, 44, 264-269.	12.1	91
115	Hepatitis B virus pre-S deletion mutations are a risk factor for hepatocellular carcinoma: a matched nested case-control study. <i>Journal of General Virology</i> , 2008, 89, 2882-2890.	2.9	91
116	Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight and Co-Medication. <i>Antiviral Therapy</i> , 2008, 13, 675-685.	1.0	90
117	Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. <i>Aids</i> , 2013, 27, 407-415.	2.2	89
118	Diabetes Mellitus, Preexisting Coronary Heart Disease, and the Risk of Subsequent Coronary Heart Disease Events in Patients Infected With Human Immunodeficiency Virus. <i>Circulation</i> , 2009, 119, 805-811.	1.6	88
119	Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter Cohorts. <i>Clinical Infectious Diseases</i> , 2013, 56, 888-897.	5.8	88
120	Incomplete Reversibility of Estimated Glomerular Filtration Rate Decline Following Tenofovir Disoproxil Fumarate Exposure. <i>Journal of Infectious Diseases</i> , 2014, 210, 363-373.	4.0	88
121	A Randomized, Controlled Trial Comparing Ganciclovir to Ganciclovir Plus Foscarnet (Each at Half) Tj ETQq1 1 0.784314 rgBT /Overl <i>Infectious Diseases</i> , 2004, 189, 1355-1361.	4.0	87
122	No Evidence for Accelerated Aging-Related Brain Pathology in Treated Human Immunodeficiency Virus: Longitudinal Neuroimaging Results From the Comorbidity in Relation to AIDS (COBRA) Project. <i>Clinical Infectious Diseases</i> , 2018, 66, 1899-1909.	5.8	86
123	HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. <i>European Journal of Neurology</i> , 2011, 18, 527-534.	3.3	85
124	Analysis of biomarker data: logs, odds ratios, and receiver operating characteristic curves. <i>Current Opinion in HIV and AIDS</i> , 2010, 5, 473-479.	3.8	83
125	Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μ L in Europe and North America: a pooled cohort observational study. <i>Lancet, The</i> , 2010, 376, 340-345.	13.7	82
126	Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation. , 1997, 52, 200-205.		81

#	ARTICLE	IF	CITATIONS
127	CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. <i>Haematologica</i> , 2009, 94, 875-880.	3.5	81
128	Risk factors associated with early hepatic artery thrombosis after orthotopic liver transplantation - univariable and multivariable analysis. <i>Transplant International</i> , 2011, 24, 401-408.	1.6	81
129	Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. <i>Aids</i> , 2006, 20, 67-71.	2.2	79
130	British HIV Association guidelines for the treatment of HIV-positive adults with antiretroviral therapy 2015. <i>HIV Medicine</i> , 2016, 17, s2-s104.	2.2	78
131	High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. <i>Aids</i> , 2010, 24, 427-435.	2.2	76
132	Effect of HCV Infection on Cause-Specific Mortality After HIV Seroconversion, Before and After 1997. <i>Gastroenterology</i> , 2013, 144, 751-760.e2.	1.3	76
133	Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. <i>Aids</i> , 2007, 21, 1717-1721.	2.2	75
134	Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples. <i>American Journal of Epidemiology</i> , 2019, 188, 1569-1577.	3.4	75
135	The effect of CMV infection on progression of human immunodeficiency virus disease in a cohort of haemophilic men followed for up to 13 years from seroconversion. <i>Epidemiology and Infection</i> , 1995, 114, 361-372.	2.1	74
136	CD4 Lymphocyte Count as a Predictor of the Duration of Highly Active Antiretroviral Therapy-Induced Suppression of Human Immunodeficiency Virus Load. <i>Journal of Infectious Diseases</i> , 1999, 180, 530-533.	4.0	74
137	Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease. <i>Journal of Internal Medicine</i> , 1998, 244, 515-522.	6.0	73
138	Human Herpesvirus 8: Seroepidemiology among Women and Detection in the Genital Tract of Seropositive Women. <i>Journal of Infectious Diseases</i> , 1999, 179, 234-236.	4.0	73
139	British HIV Association guidelines for the management of coinfection with HIV and hepatitis B or C virus 2010. <i>HIV Medicine</i> , 2010, 11, 1-30.	2.2	73
140	Impact of portal vein infiltration and type of venous reconstruction in surgery for borderline resectable pancreatic cancer. <i>British Journal of Surgery</i> , 2017, 104, 1539-1548.	0.3	73
141	Late diagnosis in the HAART era: proposed common definitions and associations with mortality. <i>Aids</i> , 2010, 24, 723-727.	2.2	72
142	Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users relative to homosexual men. <i>Aids</i> , 1996, 10, 344.	2.2	71
143	Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. <i>Eurosurveillance</i> , 2015, 20, .	7.0	70
144	DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled crossover study. <i>Haemophilia</i> , 2002, 8, 787-793.	2.1	69

#	ARTICLE	IF	CITATIONS
145	Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. <i>BMJ: British Medical Journal</i> , 2005, 330, 695.	2.3	69
146	Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. <i>Aids</i> , 2009, 23, 1689-1699.	2.2	69
147	The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. <i>Aids</i> , 2003, 17, 963-969.	2.2	68
148	Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. <i>BMC Infectious Diseases</i> , 2013, 13, 471.	2.9	68
149	Detection of antibodies to human herpesvirus 8 in Italian children: evidence for horizontal transmission. <i>British Journal of Cancer</i> , 2000, 82, 702-704.	6.4	67
150	Sexual Transmission of Hepatitis C in MSM May Not Be Confined to Those with HIV Infection. <i>Journal of Infectious Diseases</i> , 2008, 197, 1213-1214.	4.0	67
151	Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. <i>Nature Communications</i> , 2021, 12, 4450.	12.8	67
152	Health-Related Quality of Life in Individuals Infected with HIV in the Era of HAART. <i>HIV Clinical Trials</i> , 2001, 2, 484-492.	2.0	66
153	Hepatitis B, hepatitis C, and mortality among HIV-positive individuals. <i>Aids</i> , 2017, 31, 2525-2532.	2.2	66
154	Gray and White Matter Abnormalities in Treated Human Immunodeficiency Virus Disease and Their Relationship to Cognitive Function. <i>Clinical Infectious Diseases</i> , 2017, 65, 422-432.	5.8	65
155	Prognostic Importance of Anaemia in HIV Type-1-Infected Patients Starting Antiretroviral Therapy: Collaborative Analysis of Prospective Cohort Studies. <i>Antiviral Therapy</i> , 2008, 13, 959-967.	1.0	65
156	Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. <i>International Journal of Epidemiology</i> , 2002, 31, 951-958.	1.9	64
157	Relative contribution of HIV infection, demographics and body mass index to bone mineral density. <i>Aids</i> , 2014, 28, 2051-2060.	2.2	64
158	Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination?. <i>Immunology</i> , 2004, 112, 255-264.	4.4	63
159	Modelling the Cost Effectiveness of Lamivudine/Zidovudine Combination Therapy in HIV Infection. <i>Pharmacoeconomics</i> , 1997, 12, 54-66.	3.3	62
160	Cost-Utility Analysis of Primary Prophylaxis versus Treatment On-Demand for Individuals with Severe Haemophilia. <i>Pharmacoeconomics</i> , 2002, 20, 759-774.	3.3	62
161	Gender and Clinical Outcomes After Starting Highly Active Antiretroviral Treatment: A Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 29, 197-202.	2.1	61
162	Defining cognitive impairment in people-living-with-HIV: the POPPY study. <i>BMC Infectious Diseases</i> , 2016, 16, 617.	2.9	61

#	ARTICLE	IF	CITATIONS
163	Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom. <i>HIV Medicine</i> , 2017, 18, 204-213.	2.2	61
164	Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: Relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG). , 1999, 58, 182-187.		60
165	Comparison of CKD-EPI and MDRD to estimate baseline renal function in HIV-positive patients. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2291-2297.	0.7	60
166	Estimating HIV-1 Drug Resistance in Antiretroviral-Treated Individuals in the United Kingdom. <i>Journal of Infectious Diseases</i> , 2005, 192, 967-973.	4.0	59
167	Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. <i>Lancet</i> , The, 2007, 370, 1923-1928.	13.7	59
168	Use of CD4 lymphocyte count to predict long term survival free of AIDS after HIV infection. <i>BMJ: British Medical Journal</i> , 1994, 309, 309-313.	2.3	59
169	The role of apoptosis in the resolution of T cell-mediated cutaneous inflammation. <i>Journal of Immunology</i> , 1998, 161, 1619-29.	0.8	59
170	Impact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries. <i>Clinical Infectious Diseases</i> , 2012, 54, 1364-1372.	5.8	58
171	Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study. <i>Aids</i> , 2005, 19, 1627-1633.	2.2	56
172	Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1886-1896.	3.0	56
173	CD8 lymphocyte counts and serum immunoglobulin A levels early in HIV infection as predictors of CD4 lymphocyte depletion during 8 years of follow-up. <i>Aids</i> , 1993, 7, 975-980.	2.2	55
174	Neural tube defects and periconceptional folic acid in England and Wales: retrospective study Commentary: Food should be fortified with folic acid. <i>BMJ: British Medical Journal</i> , 1999, 319, 92-93.	2.3	55
175	Changes Over Time in Risk Factors for Cardiovascular Disease and Use of Lipid-Lowering Drugs in HIV-Infected Individuals and Impact on Myocardial Infarction. <i>Clinical Infectious Diseases</i> , 2008, 46, 1101-1110.	5.8	55
176	Clinical characteristics and outcomes of HIV-associated immune complex kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 2099-2107.	0.7	55
177	Cytomegalovirus polymerase chain reaction viraemia in patients receiving ganciclovir maintenance therapy for retinitis. <i>Aids</i> , 1998, 12, 605-611.	2.2	54
178	Pretreatment CD4 Cell Slope and Progression to AIDS or Death in HIV-Infected Patients Initiating Antiretroviral Therapy—The CASCADE Collaboration: A Collaboration of 23 Cohort Studies. <i>PLoS Medicine</i> , 2010, 7, e1000239.	8.4	54
179	Course of Viral Load Throughout HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 23, 172-177.	2.1	53
180	When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. <i>Aids</i> , 2003, 17, 1863-1869.	2.2	53

#	ARTICLE	IF	CITATIONS
181	Epidemiology of ageing with HIV. <i>Aids</i> , 2017, 31, S121-S128.	2.2	53
182	Changes in AIDS-Defining Illnesses in a London Clinic, 1987â€“1998. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 1999, 21, 401.	2.1	52
183	Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naïve individuals. <i>Aids</i> , 2001, 15, 2379-2384.	2.2	52
184	Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. <i>Lancet HIV</i> , 2015, 2, e335-e343.	4.7	52
185	Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. <i>Aids</i> , 2008, 22, 2461-2469.	2.2	51
186	The association of HBV core promoter double mutations (A1762T and G1764A) with viral load differs between HBeAg positive and anti-HBe positive individuals: A longitudinal analysis. <i>Journal of Hepatology</i> , 2009, 50, 273-280.	3.7	51
187	Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure. <i>Aids</i> , 2010, 24, 2239-2244.	2.2	51
188	Associations between immune depression and cardiovascular events in HIV infection. <i>Aids</i> , 2013, 27, 2735-2748.	2.2	51
189	Quantitative Effects of Valacyclovir on the Replication of Cytomegalovirus (CMV) in Persons with Advanced Human Immunodeficiency Virus Disease: Baseline CMV Load Dictates Time to Disease and Survival. <i>Journal of Infectious Diseases</i> , 1999, 180, 695-701.	4.0	50
190	The natural history of HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 1.	3.8	50
191	Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. <i>Aids</i> , 2016, 30, 1731-1743.	2.2	50
192	Survival after diagnosis of AIDS: a prospective observational study of 2625 patients. <i>BMJ: British Medical Journal</i> , 1997, 314, 409-409.	2.3	50
193	Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. <i>Antiviral Therapy</i> , 2008, 13, 959-67.	1.0	50
194	Impact of Switching From Zidovudine to Tenofovir Disoproxil Fumarate on Bone Mineral Density and Markers of Bone Metabolism in Virologically Suppressed HIV-1 Infected Patients; A Substudy of the PREPARE Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1659-1666.	3.6	49
195	Staging system for clinical AIDS patients. <i>Lancet, The</i> , 1995, 346, 12-17.	13.7	48
196	Valacyclovir Provides Optimum Acyclovir Exposure for Prevention of Cytomegalovirus and Related Outcomes after Organ Transplantation. <i>Journal of Infectious Diseases</i> , 2002, 186, S110-S115.	4.0	48
197	Human Serum Amyloid P Component Protects against <i>Escherichia coli</i> O157:H7 Shiga Toxin 2 In Vivo: Therapeutic Implications for Hemolyticâ€“Uremic Syndrome. <i>Journal of Infectious Diseases</i> , 2006, 193, 1120-1124.	4.0	48
198	Clinical epidemiology of HIV-associated end-stage renal failure in the UK. <i>Aids</i> , 2009, 23, 2517-2521.	2.2	48

#	ARTICLE	IF	CITATIONS
199	The Effect of Valaciclovir on Cytomegalovirus Viremia and Viruria Detected by Polymerase Chain Reaction in Patients with Advanced Human Immunodeficiency Virus Disease. <i>Journal of Infectious Diseases</i> , 1998, 177, 57-64.	4.0	47
200	Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. <i>Lancet HIV</i> , 2017, 4, e295-e302.	4.7	47
201	Pain in people living with HIV and its association with healthcare resource use, well being and functional status. <i>Aids</i> , 2018, 32, 2697-2706.	2.2	47
202	Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. <i>Antiviral Therapy</i> , 2008, 13, 675-85.	1.0	47
203	The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. <i>Aids</i> , 1999, 13, 1255-1261.	2.2	46
204	The impact of HIV on mortality rates in the complete UK haemophilia population. <i>Aids</i> , 2004, 18, 525-533.	2.2	46
205	Definition and epidemiology of late presentation in Europe. <i>Antiviral Therapy</i> , 2010, 15, 3-8.	1.0	46
206	Antiretroviral therapy CNS penetration and HIV-associated CNS disease. <i>Neurology</i> , 2011, 76, 693-700.	1.1	46
207	Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate. <i>Journal of Infection</i> , 2017, 74, 492-500.	3.3	46
208	The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges. <i>Clinical Infectious Diseases</i> , 2017, 64, 1644-1656.	5.8	46
209	The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4-8 viral load. <i>Aids</i> , 2001, 15, 47-54.	2.2	45
210	Baseline Kidney Function as Predictor of Mortality and Kidney Disease Progression in HIV-Positive Patients. <i>American Journal of Kidney Diseases</i> , 2012, 60, 539-547.	1.9	45
211	Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe. <i>HIV Medicine</i> , 2017, 18, 171-180.	2.2	45
212	Reproductive choices of women in families with haemophilia. <i>Haemophilia</i> , 2000, 6, 33-40.	2.1	44
213	Course of Viral Load Throughout HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 23, 172-177.	2.1	44
214	Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population. <i>HIV Medicine</i> , 2004, 5, 88-92.	2.2	44
215	Haemoglobin and albumin as markers of HIV disease progression in the highly active antiretroviral therapy era: relationships with gender. <i>HIV Medicine</i> , 2007, 8, 38-45.	2.2	44
216	Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. <i>BMJ</i> , 2012, 345, e5253-e5253.	6.0	44

#	ARTICLE	IF	CITATIONS
217	Natural history of HIV-control since seroconversion. <i>Aids</i> , 2013, 27, 2451-2460.	2.2	44
218	Increased risk of cardiovascular disease (<scp>CVD</scp>) with age in <scp>HIV</scp>-positive men: a comparison of the <scp>D</scp>:<scp>A</scp>:<scp>D CVD</scp> risk equation and general population <scp>CVD</scp> risk equations. <i>HIV Medicine</i> , 2014, 15, 595-603.	2.2	44
219	Polypharmacy and Drug-drug Interactions in Older and Younger People Living with HIV: The POPPY Study. <i>Antiviral Therapy</i> , 2019, 24, 193-201.	1.0	44
220	Human Immunodeficiency Virus Rebound after Suppression to <400 Copies/mL during Initial Highly Active Antiretroviral Therapy Regimens, according to Prior Nucleoside Experience and Duration of Suppression. <i>Journal of Infectious Diseases</i> , 2002, 186, 1086-1091.	4.0	43
221	Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study[*]. <i>HIV Medicine</i> , 2010, 11, 152-160.	2.2	43
222	Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. <i>International Journal of Epidemiology</i> , 2016, 45, 2038-2049.	1.9	43
223	Predictors of hypertension and changes of blood pressure in HIV-infected patients. <i>Antiviral Therapy</i> , 2005, 10, 811-23.	1.0	43
224	Substantial Correlation between HIV Type 1 Drug-Associated Resistance Mutations in Plasma and Peripheral Blood Mononuclear Cells in Treatment-Experienced Patients. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1025-1030.	1.1	42
225	Antiretroviral Drug-Related Liver Mortality Among HIV-Positive Persons in the Absence of Hepatitis B or C Virus Coinfection: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Clinical Infectious Diseases</i> , 2013, 56, 870-879.	5.8	42
226	The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load. <i>Aids</i> , 2000, 14, 2129-2136.	2.2	41
227	Assessing the cost-effectiveness of HAART for adults with HIV in England. <i>HIV Medicine</i> , 2001, 2, 52-58.	2.2	41
228	An unusual form of autoimmune hepatitis in young Somalian men. <i>Liver International</i> , 2005, 25, 325-330.	3.9	41
229	Success of Clinical Care for Human Immunodeficiency Virus Infection According to Demographic Group Among Sexually Infected Patients in a Routine Clinic Population, 1999 to 2004. <i>Archives of Internal Medicine</i> , 2007, 167, 692.	3.8	41
230	Cancer Risk and Use of Protease Inhibitor or Nonnucleoside Reverse Transcriptase Inhibitor-Based Combination Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 568-577.	2.1	41
231	Outcome of R1 resection in patients undergoing pancreatico-duodenectomy for pancreatic cancer. <i>European Journal of Surgical Oncology</i> , 2008, 34, 1309-1315.	1.0	40
232	Structural Brain Abnormalities in Successfully Treated HIV Infection: Associations With Disease and Cerebrospinal Fluid Biomarkers. <i>Journal of Infectious Diseases</i> , 2018, 217, 69-81.	4.0	40
233	Risk of new AIDS diseases in people on triple therapy. <i>Lancet, The</i> , 1999, 353, 463.	13.7	39
234	The changing clinical epidemiology of AIDS in the highly active antiretroviral therapy era. <i>Aids</i> , 2002, 16, S61-S68.	2.2	39

#	ARTICLE	IF	CITATIONS
235	The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK – trends in HCV testing and the impact of HCV on HIV treatment outcomes. <i>Journal of Viral Hepatitis</i> , 2010, 17, 569-577.	2.0	39
236	Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. <i>Aids</i> , 2011, 25, 1497-1504.	2.2	39
237	Hepatitis delta virus testing, epidemiology and management: A multicentre cross-sectional study of patients in London. <i>Journal of Clinical Virology</i> , 2015, 66, 33-37.	3.1	39
238	Acquired Immunodeficiency Syndrome (AIDS) Risk in Recent and Long-standing Human Immunodeficiency Virus Type 1 (HIV-1)-infected Patients with Similar CD4 Lymphocyte Counts. <i>American Journal of Epidemiology</i> , 1993, 138, 870-878.	3.4	38
239	Designing and interpreting HIV noninferiority trials in naive and experienced patients. <i>Aids</i> , 2008, 22, 913-921.	2.2	38
240	Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention?. <i>Aids</i> , 2009, 23, 2507-2515.	2.2	38
241	Rating evidence in treatment guidelines. <i>Aids</i> , 2013, 27, 1839-1846.	2.2	38
242	Body Mass Index and the Risk of Serious Non-AIDS Events and All-Cause Mortality in Treated HIV-Positive Individuals: D:A:D Cohort Analysis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 78, 579-588.	2.1	38
243	Prevalence of Hepatitis C-Related Cirrhosis in Elderly Asian Patients Infected in Childhood. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 910-917.	4.4	37
244	Stability of antiretroviral regimens in patients with viral suppression. <i>Aids</i> , 2008, 22, 1039-1046.	2.2	37
245	Resistance Profiles in Patients with Viral Rebound on Potent Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2000, 181, 1143-1147.	4.0	36
246	CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003. <i>HIV Medicine</i> , 2007, 8, 135-141.	2.2	36
247	Late HIV presentation: epidemiology, clinical implications and management. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 877-889.	4.4	36
248	Outcomes in the First Year after Initiation of First-Line Haart among Heterosexual Men and Women in the Uk Chic Study. <i>Antiviral Therapy</i> , 2011, 16, 805-814.	1.0	36
249	Outcome after pancreaticoduodenectomy for T3 adenocarcinoma: A multivariable analysis from the UK Vascular Resection for Pancreatic Cancer Study Group. <i>European Journal of Surgical Oncology</i> , 2015, 41, 1500-1507.	1.0	36
250	Growing up with perinatal HIV: changes in clinical outcomes before and after transfer to adult care in the UK. <i>Journal of the International AIDS Society</i> , 2017, 20, 21577.	3.0	36
251	Highly active antiretroviral therapy and cervical intraepithelial neoplasia. <i>Aids</i> , 2002, 16, 927-929.	2.2	36
252	The Rate of Viral Rebound after Attainment of an HIV Load <50 Copies/mL According to Specific Antiretroviral Drugs in Use: Results from a Multicenter Cohort Study. <i>Journal of Infectious Diseases</i> , 2005, 192, 1387-1397.	4.0	35

#	ARTICLE	IF	CITATIONS
253	HBV or HCV Coinfections and Risk of Myocardial Infarction in HIV-Infected Individuals: The D:A:D Cohort Study. <i>Antiviral Therapy</i> , 2010, 15, 1077-1086.	1.0	35
254	Patterns of Co-occurring Comorbidities in People Living With HIV. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy272.	0.9	35
255	Relationship between serum ferritin, hepatic iron staining, diabetes mellitus and fibrosis progression in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 519-524.	3.7	34
256	Incidence and risk factors for the development of prolonged and severe intrahepatic cholestasis after liver transplantation. <i>Liver Transplantation</i> , 2006, 12, 1626-1633.	2.4	34
257	Renal Impairment and Cardiovascular Disease in HIV-Positive Individuals: The D:A:D Study. <i>Journal of Infectious Diseases</i> , 2016, 214, 1212-1220.	4.0	34
258	Terminal differentiation of T cells is strongly associated with CMV infection and increased in HIV-positive individuals on ART and lifestyle matched controls. <i>PLoS ONE</i> , 2017, 12, e0183357.	2.5	34
259	A continuum of HIV care describing mortality and loss to follow-up: a longitudinal cohort study. <i>Lancet HIV</i> , 2018, 5, e301-e308.	4.7	34
260	HIV in the UK 1980â€“2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy. <i>HIV Medicine</i> , 2007, 8, 536-546.	2.2	33
261	Presence of the Metabolic Syndrome Is Not a Better Predictor of Cardiovascular Disease Than the Sum of Its Components in HIV-Infected Individuals: Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) study. <i>Diabetes Care</i> , 2009, 32, 474-480.	8.6	33
262	Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field. <i>Clinical Trials</i> , 2010, 7, 19-35.	1.6	33
263	Cohort profile: The Pharmacokinetic and clinical Observations in PeoPle over fifty (POPPY) study. <i>International Journal of Epidemiology</i> , 2018, 47, 1391-1392e.	1.9	33
264	Assessing health-related quality-of-life in patients with severe haemophilia A and B. <i>Psychology, Health and Medicine</i> , 1999, 4, 5-15.	2.4	32
265	Which aspects of health care are most valued by people living with HIV in high-income countries? A systematic review. <i>BMC Health Services Research</i> , 2016, 16, 677.	2.2	32
266	Medicalising normality? Using a simulated dataset to assess the performance of different diagnostic criteria of HIV-associated cognitive impairment. <i>PLoS ONE</i> , 2018, 13, e0194760.	2.5	32
267	Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men. <i>Aids</i> , 2001, 15, 2051-2053.	2.2	32
268	Pre-AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual men. <i>Aids</i> , 2000, 14, 1829-1837.	2.2	31
269	An audit of antiretroviral treatment use in HIV-infected patients in a London clinic: the limitations of observational databases when auditing antiretroviral treatment use. <i>HIV Medicine</i> , 2003, 4, 87-93.	2.2	31
270	Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study. <i>HIV Medicine</i> , 2011, 12, 583-593.	2.2	31

#	ARTICLE	IF	CITATIONS
271	The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. <i>Aids</i> , 2012, 26, 1691-1705.	2.2	31
272	Orthopaedic Surgery in Hemophilic Patients With Human Immunodeficiency Virus. <i>Clinical Orthopaedics and Related Research</i> , 1997, 343, 81-87.	1.5	30
273	Markers of HIV-1 disease progression in individuals with haemophilia coinfecting with hepatitis C virus: a longitudinal study. <i>Lancet</i> , 2002, 360, 1546-1551.	13.7	30
274	Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. <i>Aids</i> , 2007, 21, 1423-1430.	2.2	30
275	Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1354-9.	3.0	30
276	Predictors of longitudinal change in bone mineral density in a cohort of HIV-positive and negative patients. <i>Aids</i> , 2017, 31, 643-652.	2.2	30
277	Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. <i>PLoS ONE</i> , 2017, 12, e0173893.	2.5	30
278	The Progression of HIV disease in a haemophilic cohort followed for 12 years. <i>British Journal of Haematology</i> , 1993, 83, 330-333.	2.5	29
279	Observing the process of care: a stroke unit, elderly care unit and general medical ward compared. <i>Age and Ageing</i> , 1999, 28, 433-440.	1.6	29
280	Findings from the first national clinical audit of treatment for people with HIV. <i>HIV Medicine</i> , 2003, 4, 11-17.	2.2	29
281	HIV-1 DRUG RESISTANCE IN HIV-1-INFECTED CHILDREN IN THE UNITED KINGDOM FROM 1998 TO 2004. <i>Pediatric Infectious Disease Journal</i> , 2008, 27, 457-459.	2.0	29
282	Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study. <i>Journal of the International AIDS Society</i> , 2014, 17, 19512.	3.0	29
283	Is HIV Painful? An Epidemiologic Study of the Prevalence and Risk Factors for Pain in HIV-infected Patients. <i>Clinical Journal of Pain</i> , 2015, 31, 813-819.	1.9	29
284	Rapid reconstitution of humoral immunity against cytomegalovirus but not HIV following highly active antiretroviral therapy. <i>Aids</i> , 2002, 16, 2129-2135.	2.2	28
285	Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations. <i>HIV Medicine</i> , 2010, 11, 432-438.	2.2	28
286	Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV-positive persons: the Data Collection on Adverse Events of Antiretroviral Drugs (D:A:D) study. <i>HIV Medicine</i> , 2018, 19, 605-618.	2.2	28
287	Depression, lifestyle factors and cognitive function in people living with HIV and comparable HIV-negative controls. <i>HIV Medicine</i> , 2019, 20, 274-285.	2.2	28
288	Hepatitis B Virus Infection in HIV-Positive Individuals in the UK Collaborative HIV Cohort (UK CHIC) Study. <i>PLoS ONE</i> , 2012, 7, e49314.	2.5	28

#	ARTICLE	IF	CITATIONS
289	Immune markers and viral load after HIV-1 seroconversion as predictors of disease progression in a cohort of haemophilic men. <i>Aids</i> , 1998, 12, 1347-1352.	2.2	27
290	Primary prophylaxis for individuals with severe haemophilia: how many hospital visits could treatment prevent?. <i>Journal of Internal Medicine</i> , 2000, 247, 493-499.	6.0	27
291	Evaluation of HIV Protease Inhibitor Use and the Risk of Sudden Death or Nonhemorrhagic Stroke. <i>Journal of Infectious Diseases</i> , 2012, 205, 535-539.	4.0	27
292	The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort. <i>Journal of Infection</i> , 2014, 68, 77-84.	3.3	27
293	The influence of host factors and immunogenetics on lymphocyte responses to HepageneS vaccination. <i>Vaccine</i> , 1999, 17, 1329-1337.	3.8	26
294	Use of Viral Load Measured After 4 Weeks of Highly Active Antiretroviral Therapy to Predict Virologic Outcome at 24 Weeks for HIV-1???Positive Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 37, 1155-1159.	2.1	26
295	Outpatient medical management of missed miscarriage using misoprostol. <i>Journal of Obstetrics and Gynaecology</i> , 2007, 27, 283-286.	0.9	26
296	Effect of Baseline CD4 Cell Counts on the Clinical Significance of Short-Term Immunologic Response to Antiretroviral Therapy in Individuals With Virologic Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 357-363.	2.1	26
297	Should HIV therapy be started at a CD4 cell count above 350 cells/µl in asymptomatic HIV-1-infected patients?. <i>Current Opinion in Infectious Diseases</i> , 2009, 22, 191-197.	3.1	26
298	A complex hepatitis B virus (X/C) recombinant is common in Long An county, Guangxi and may have originated in southern China. <i>Journal of General Virology</i> , 2011, 92, 402-411.	2.9	26
299	Risk of tuberculosis following HIV seroconversion in high-income countries. <i>Thorax</i> , 2013, 68, 207-213.	5.6	26
300	Association between engagement in-care and mortality in HIV-positive persons. <i>Aids</i> , 2017, 31, 653-660.	2.2	26
301	Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir. <i>Aids</i> , 2017, 31, 485-492.	2.2	26
302	Predictive Performance of Cardiovascular Disease Risk Prediction Algorithms in People Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 562-571.	2.1	26
303	Two decades of HIV infection in a cohort of haemophilic individuals: clinical outcomes and response to highly active antiretroviral therapy. <i>Aids</i> , 2000, 14, 1001-1007.	2.2	25
304	The Impact of Transmitted Drug-Resistance on Treatment Selection and Outcome of First-Line Highly Active Antiretroviral Therapy (HAART). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 53, 633-639.	2.1	25
305	Data linkage reduces loss to follow-up in an observational HIV cohort study. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 1101-1109.	5.0	25
306	Antiviral therapy. <i>Nature</i> , 1995, 375, 195-195.	27.8	24

#	ARTICLE	IF	CITATIONS
307	What is the risk of mortality following diagnosis of multidrug-resistant HIV-1?. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 705-713.	3.0	24
308	The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy. <i>HIV Medicine</i> , 2009, 10, 35-43.	2.2	24
309	Simultaneous measurement of urinary albumin and total protein may facilitate decision-making in HIV-infected patients with proteinuria. <i>HIV Medicine</i> , 2012, 13, 526-532.	2.2	24
310	The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy. <i>Aids</i> , 2015, 29, 2269-2278.	2.2	24
311	Associations between cognitive impairment and patient-reported measures of physical/mental functioning in older people living with HIV. <i>HIV Medicine</i> , 2017, 18, 363-369.	2.2	24
312	Cytomegalovirus Seropositivity and Human Immunodeficiency Virus Type 1 RNA Levels in Individuals with Hemophilia. <i>Journal of Infectious Diseases</i> , 2000, 181, 1800-1803.	4.0	23
313	Chlamydial co-infection among patients with gonorrhoea. <i>International Journal of STD and AIDS</i> , 2002, 13, 261-263.	1.1	23
314	Pitfalls of Assessing Hepatotoxicity in Trials and Observational Cohorts. <i>Clinical Infectious Diseases</i> , 2004, 38, S56-S64.	5.8	23
315	The attitude of patients towards medical students in a sexual health clinic. <i>Sexually Transmitted Infections</i> , 2005, 81, 437-439.	1.9	23
316	Herpes Simplex Virus Type 2 (HSV-2) Seroprevalence at the Time of HIV-1 Diagnosis and Seroincidence After HIV-1 Diagnosis in an Ethnically Diverse Cohort of HIV-1-Infected Persons. <i>Sexually Transmitted Diseases</i> , 2006, 33, 96-101.	1.7	23
317	Factors influencing lopinavir and atazanavir plasma concentration. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 129-137.	3.0	23
318	Establishing the cascade of care for hepatitis C in England—benchmarking to monitor impact of direct acting antivirals. <i>Journal of Viral Hepatitis</i> , 2018, 25, 482-490.	2.0	23
319	The inhibition of cutaneous T cell apoptosis may prevent resolution of inflammation in atopic eczema. <i>Clinical and Experimental Immunology</i> , 2000, 122, 150-156.	2.6	22
320	Relationship between IgM Antibody to Human Cytomegalovirus, Virus Load, Donor and Recipient Serostatus, and Administration of Methylprednisolone as Risk Factors for Cytomegalovirus Disease after Liver Transplantation. <i>Journal of Infectious Diseases</i> , 2000, 182, 1610-1615.	4.0	22
321	Blood and graft eosinophils in acute cellular rejection of liver allografts. <i>Transplantation Proceedings</i> , 2001, 33, 2588-2593.	0.6	22
322	Short-Term CD4 Cell Response After Highly Active Antiretroviral Therapy Initiated at Different Times From Seroconversion in 1500 Seroconverters. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 32, 303-310.	2.1	22
323	Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK. <i>HIV Medicine</i> , 2008, 9, 47-56.	2.2	22
324	Renal tubular disease in the era of combination antiretroviral therapy. <i>Aids</i> , 2015, 29, 1831-1836.	2.2	22

#	ARTICLE	IF	CITATIONS
325	When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 72, 214-221.	2.1	22
326	A qualitative assessment of the acceptability of hepatitis C remote self-testing and self-sampling amongst people who use drugs in London, UK. <i>BMC Infectious Diseases</i> , 2018, 18, 281.	2.9	22
327	Is There a General Tendency for CD4 Lymphocyte Decline to Speed Up during Human Immunodeficiency Virus Infection? Evidence from the Italian Seroconversion Study. <i>Journal of Infectious Diseases</i> , 1997, 175, 775-780.	4.0	21
328	The changing patterns of factor VIII (FVIII) and factor IX (FIX) clotting factor usage in a comprehensive care centre between 1980 and 1994. <i>Haemophilia</i> , 1998, 4, 4-9.	2.1	21
329	Effects of highly active antiretroviral therapy on paediatric metabolite levels. <i>HIV Medicine</i> , 2006, 7, 16-24.	2.2	21
330	End-Stage Kidney Disease and Kidney Transplantation in HIV-Positive Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 67, 177-180.	2.1	21
331	HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naïve and -experienced patients in the UK. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3487-3494.	3.0	21
332	Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 650-657.	5.8	21
333	The association between severe menopausal symptoms and engagement with HIV care and treatment in women living with HIV. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 101-108.	1.2	21
334	Effect of Coinfection With Hepatitis G Virus on HIV Disease Progression in Hemophilic Men. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 19, 546-547.	0.3	20
335	The Relationships between Ethnicity, Sex, Risk Group, and Virus Load in Human Immunodeficiency Virus Type 1 Antiretroviral-naïve Patients. <i>Journal of Infectious Diseases</i> , 2001, 183, 1518-1521.	4.0	20
336	Drug resistance is uncommon in pregnant women with low viral loads taking zidovudine monotherapy to prevent perinatal HIV transmission. <i>Aids</i> , 2003, 17, 2665-2667.	2.2	20
337	Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters. <i>HIV Medicine</i> , 2011, 12, 289-298.	2.2	20
338	Predictors of pregnancy and changes in pregnancy incidence among HIV-positive women accessing HIV clinical care. <i>Aids</i> , 2013, 27, 95-103.	2.2	20
339	Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw009.	0.9	20
340	Longitudinal Analysis of the Associations between Antiretroviral Therapy, Viraemia and Immunosuppression with Lipid Levels: The D:A:D Study. <i>Antiviral Therapy</i> , 2016, 21, 495-506.	1.0	20
341	Sleep Disorders in Human Immunodeficiency Virus: A Substudy of the Pharmacokinetics and Clinical Observations in People Over Fifty (POPPY) Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa561.	0.9	20
342	Hospital costs of treating haemophilic patients infected with HIV. <i>Aids</i> , 1995, 9, 787-794.	2.2	19

#	ARTICLE	IF	CITATIONS
343	The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults. <i>Aids</i> , 2013, 27, 2245-2253.	2.2	19
344	CD4 cell count changes in individuals with counts above 500 cells/mm ³ and viral loads below 50 copies/ml on antiretroviral therapy. <i>Aids</i> , 2002, 16, 1073-1075.	2.2	19
345	Response to Efavirenz-Containing Regimens in Previously Antiretroviral-Naive HIV-Positive Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 62-67.	2.1	19
346	Beta-2 microglobulin as a predictor of prognosis in HIV-infected men with haemophilia: a proposed strategy for use in clinical care. <i>British Journal of Haematology</i> , 1994, 86, 366-371.	2.5	18
347	Changes in AIDS-Defining Illnesses in a London Clinic, 1987-1998. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1999, 21, 401.	0.3	18
348	Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?. <i>Aids</i> , 2008, 22, 349-356.	2.2	18
349	PRIME (Positive Transitions Through the Menopause) Study: a protocol for a mixed-methods study investigating the impact of the menopause on the health and well-being of women living with HIV in England. <i>BMJ Open</i> , 2019, 9, e025497.	1.9	18
350	Risk factors and impact of patterns of co-occurring comorbidities in people living with HIV. <i>Aids</i> , 2019, 33, 1871-1880.	2.2	18
351	Shorter survival in HIV-positive patients with diarrhoea who excrete adenovirus from the GI tract. , 1999, 58, 280-285.		17
352	Treatment comparisons in HIV infection: the benefits and limitations of observational cohort studies. <i>Journal of Antimicrobial Chemotherapy</i> , 2001, 47, 371-375.	3.0	17
353	Determinants of response to first HAART regimen in antiretroviral-naive patients with an estimated time since HIV seroconversion. <i>HIV Medicine</i> , 2006, 7, 1-9.	2.2	17
354	British HIV Association (BHIVA) national cohort outcomes audit of patients commencing antiretrovirals from naïve. <i>HIV Medicine</i> , 2009, 10, 337-342.	2.2	17
355	High-density lipoprotein levels and 10-year cardiovascular risk in HIV-1-infected patients. <i>Aids</i> , 2011, 25, 867-869.	2.2	17
356	Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study. <i>Lancet HIV</i> , 2014, 1, e41-e48.	4.7	17
357	The menopause transition in women living with HIV: current evidence and future avenues of research. <i>Journal of Virus Eradication</i> , 2016, 2, 114-116.	0.5	17
358	A discrete choice experiment to assess people living with HIV's (PLWHIV's) preferences for GP or HIV clinic appointments. <i>Sexually Transmitted Infections</i> , 2017, 93, 105-111.	1.9	17
359	Development and application of a new measure of engagement in out-patient HIV care. <i>HIV Medicine</i> , 2017, 18, 267-274.	2.2	17
360	Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study. <i>PLoS Medicine</i> , 2017, 14, e1002424.	8.4	17

#	ARTICLE	IF	CITATIONS
361	High Cellular Monocyte Activation in People Living With Human Immunodeficiency Virus on Combination Antiretroviral Therapy and Lifestyle-Matched Controls Is Associated With Greater Inflammation in Cerebrospinal Fluid. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx108.	0.9	17
362	Cardiovascular disease in HIV patients: recent advances in predicting and managing risk. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 677-688.	4.4	17
363	CD4+ Counts before and after Switching to Monoclonal High-Purity Factor VIII Concentrate in HIV-Infected Haemophilic Patients. <i>Thrombosis and Haemostasis</i> , 1994, 72, 214-217.	3.4	17
364	HIV/HCV coinfection, HAART, and liver-related mortality. <i>Lancet, The</i> , 2004, 364, 757-758.	13.7	16
365	Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. <i>Aids</i> , 2008, 22, 1943-1950.	2.2	16
366	Improvements in cheek volume in lipotrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors. <i>HIV Medicine</i> , 2009, 10, 351-355.	2.2	16
367	Survival Outcomes and Effect of Early vs. Deferred cART Among HIV-Infected Patients Diagnosed at the Time of an AIDS-Defining Event: A Cohort Analysis. <i>PLoS ONE</i> , 2011, 6, e26009.	2.5	16
368	Response to antiviral therapy in patients with genotype 3 chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 747-753.	1.6	16
369	Adverse Outcome Analyses of Observational Data: Assessing Cardiovascular Risk in HIV Disease. <i>Clinical Infectious Diseases</i> , 2012, 54, 408-413.	5.8	16
370	Biomarkers to Monitor Safety in People on ART and Risk of Mortality. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 60, 51-58.	2.1	16
371	The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study. <i>CMAJ Open</i> , 2014, 2, E318-E329.	2.4	16
372	Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals. <i>Aids</i> , 2017, 31, 1261-1270.	2.2	16
373	Reference curves for CD4 cell count response to combination antiretroviral therapy in HIV-infected treatment-naïve patients. <i>HIV Medicine</i> , 2017, 18, 33-44.	2.2	16
374	Cardiovascular disease in women living with HIV: A narrative review. <i>Maturitas</i> , 2018, 108, 58-70.	2.4	16
375	Effect of Changes in Body Mass Index on the Risk of Cardiovascular Disease and Diabetes Mellitus in HIV-Positive Individuals: Results From the D:A:D Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 86, 579-586.	2.1	16
376	The effects of the 32-bp CCR-5 deletion on HIV transmission and HIV disease progression in individuals with haemophilia. <i>British Journal of Haematology</i> , 2000, 111, 136-142.	2.5	16
377	??-GLUTATHIONE-S-TRANSFERASE IN ACUTE REJECTION OF LIVER TRANSPLANT RECIPIENTS1. <i>Transplantation</i> , 1998, 65, 401-405.	1.0	16
378	A Practical Guide to Applying the Intention-to-Treat Principle to Clinical Trials in HIV Infection. <i>HIV Clinical Trials</i> , 2000, 1, 31-38.	2.0	15

#	ARTICLE	IF	CITATIONS
379	Reduction in Human Immunodeficiency Virus Type 1 Mutations Associated with Drug Resistance after Initiating New Therapeutic Regimens in Pretreated Patients. <i>Journal of Infectious Diseases</i> , 2000, 181, 1804-1807.	4.0	15
380	Changes in Outcome of Persons Initiating Highly Active Antiretroviral Therapy at a CD4 Count Less Than 50 Cells/mm ³ . <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 202-205.	2.1	15
381	Limiting Cumulative HIV Viremia Copy-Years by Early Treatment Reduces Risk of AIDS and Death. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 100-108.	2.1	15
382	Lopinavir and atazanavir in pregnancy: comparable infant outcomes, virological efficacies and preterm delivery rates. <i>HIV Medicine</i> , 2016, 17, 28-35.	2.2	15
383	Abacavir use and risk of recurrent myocardial infarction. <i>Aids</i> , 2018, 32, 79-88.	2.2	15
384	Self-management Interventions for Pain and Physical Symptoms Among People Living With HIV: A Systematic Review of the Evidence. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 206-225.	2.1	15
385	Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study. <i>EClinicalMedicine</i> , 2019, 13, 91-100.	7.1	15
386	Associations Between Widespread Pain and Sleep Quality in People With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 106-112.	2.1	15
387	Influence of HIV-1 infection on GBV-C infection in multiply infected haemophilic patients. , 1998, 56, 316-320.		14
388	The rate of CD4 decline as a determinant of progression to AIDS independent of the most recent CD4 count. <i>Epidemiology and Infection</i> , 1998, 121, 369-376.	2.1	14
389	Long-Term Follow-Up of Antiretroviral-Naive HIV-Positive Patients Treated With Nevirapine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 26, 462-465.	2.1	14
390	Immunological changes during treatment interruptions. <i>Aids</i> , 2003, 17, 126-128.	2.2	14
391	Cervical screening in HIV-positive women: characteristics of those who default and attitudes towards screening. <i>HIV Medicine</i> , 2006, 7, 46-52.	2.2	14
392	Differential Effects of Prednisolone and Azathioprine on the Development of Human Cytomegalovirus Replication Post Liver Transplantation. <i>Transplantation</i> , 2007, 84, 605-610.	1.0	14
393	Decline of CD4+ T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals. <i>Aids</i> , 2011, 25, 1041-1049.	2.2	14
394	How have guidelines on when to start antiretroviral therapy affected survival of people living with HIV infection?. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 487-491.	3.8	14
395	Level of agreement between frequently used cardiovascular risk calculators in people living with HIV. <i>HIV Medicine</i> , 2019, 20, 347-352.	2.2	14
396	The Cost-Effectiveness of Triple Nucleoside Analogue Therapy Antiretroviral Regimens in the Treatment of HIV in the United Kingdom. <i>HIV Clinical Trials</i> , 2000, 1, 27-35.	2.0	13

#	ARTICLE	IF	CITATIONS
397	Higher vaginal pH is associated with Chlamydia trachomatis infection in women: a prospective caseâ€“controlled study. International Journal of STD and AIDS, 2005, 16, 290-293.	1.1	13
398	A Study of the Incidence of Accidents Occurring during an Arctic Expedition: Another Important Aspect of Travel Medicine?. Journal of Travel Medicine, 2000, 7, 205-207.	3.0	13
399	Abacavir and increased risk of myocardial infarction â€“ Authors' reply. Lancet, The, 2008, 372, 804-805.	13.7	13
400	Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study. Journal of Antimicrobial Chemotherapy, 2013, 68, 2339-43.	3.0	13
401	Association Between ALT Level and the Rate of Cardio/Cerebrovascular Events in HIV-Positive Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 456-463.	2.1	13
402	Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. Aids, 2015, 29, 193-200.	2.2	13
403	Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance. Aids, 2018, 32, 327-335.	2.2	13
404	Chronic Kidney Disease Risk in African and Caribbean Populations With HIV. Journal of Infectious Diseases, 2018, 218, 1767-1772.	4.0	13
405	Magnetic Resonance Imaging of Cerebral Small Vessel Disease in Men Living with HIV and HIV-Negative Men Aged 50 and Above. AIDS Research and Human Retroviruses, 2019, 35, 453-460.	1.1	13
406	Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIVâ€“positive individuals. Statistics in Medicine, 2019, 38, 2428-2446.	1.6	13
407	Ethnic inequalities in mental health and socioeconomic status among older women living with HIV: results from the PRIME Study. Sexually Transmitted Infections, 2022, 98, 128-131.	1.9	13
408	Conventional cardiovascular risk factors in HIV infection: how conventional are they?. Current Opinion in HIV and AIDS, 2008, 3, 214-219.	3.8	12
409	Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 311-318.	2.1	12
410	Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma. Journal of the National Cancer Institute, 2018, 110, 598-607.	6.3	12
411	High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment. Journal of Antimicrobial Chemotherapy, 2020, 75, 1575-1579.	3.0	12
412	The epidemiology of kidney disease in people of African ancestry with HIV in the UK. EclinicalMedicine, 2021, 38, 101006.	7.1	12
413	COVIDâ€“19 mortality among people with diagnosed HIV compared to those without during the first wave of the COVIDâ€“19 pandemic in England. HIV Medicine, 2022, 23, 90-102.	2.2	12
414	Viral breakthrough after suppression with highly active antiretroviral therapy. Aids, 2003, 17, 768-770.	2.2	12

#	ARTICLE	IF	CITATIONS
415	The "Comorbidity in Relation to AIDS" (COBRA) cohort: Design, methods and participant characteristics. <i>PLoS ONE</i> , 2018, 13, e0191791.	2.5	12
416	REACH: a mixed-methods study to investigate the measurement, prediction and improvement of retention and engagement in outpatient HIV care. <i>Health Services and Delivery Research</i> , 2017, 5, 1-160.	1.4	12
417	Immunodeficiency and the risk of death in HIV infection. <i>JAMA - Journal of the American Medical Association</i> , 1992, 268, 2662-6.	7.4	12
418	Comorbidities in women living with HIV: A systematic review. <i>HIV Medicine</i> , 2022, 23, 331-361.	2.2	12
419	The Relationship between Cd4 Cell Count Nadirs and the Toxicity Profiles of Antiretroviral Regimens. <i>Antiviral Therapy</i> , 2005, 10, 459-467.	1.0	12
420	Morbidity and mortality from transfusion-transmitted disease in haemophilia. <i>Lancet</i> , 1995, 345, 1309.	13.7	11
421	The relationship between beta-2-microglobulin, CD4 lymphocyte count, AIDS and death in HIV-positive individuals. <i>Epidemiology and Infection</i> , 1997, 118, 259-266.	2.1	11
422	A practical approach to adjusting for attrition bias in HIV clinical trials with serial marker responses. <i>Aids</i> , 1998, 12, 1155-1161.	2.2	11
423	The Prognostic Value of a Single Hepatitis C Virus RNA Load Measurement Taken Early after Human Immunodeficiency Virus Seroconversion. <i>Journal of Infectious Diseases</i> , 2002, 186, 470-476.	4.0	11
424	Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception. <i>Aids</i> , 2011, 25, 1647-1655.	2.2	11
425	How likely is environmental or patient cross-contamination of <i>Chlamydia trachomatis</i> DNA to lead to false positive results in patients attending our clinic?: Table A1. <i>Sexually Transmitted Infections</i> , 2013, 89, 105-107.	1.9	11
426	The effects of age on associations between markers of HIV progression and markers of metabolic function including albumin, haemoglobin and lipid concentrations. <i>HIV Medicine</i> , 2014, 15, 311-316.	2.2	11
427	Host, disease, and antiretroviral factors are associated with normalization of the CD4:CD8 ratio after initiating antiretroviral therapy. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 1682-1685.e1.	2.9	11
428	No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom. <i>Journal of Infectious Diseases</i> , 2016, 214, 1302-1308.	4.0	11
429	First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines. <i>Aids</i> , 2020, 34, 1823-1831.	2.2	11
430	Population Trends in the Prevalence and Patterns of Protease Resistance Related to Exposure to Unboosted and Boosted Protease Inhibitors. <i>Antiviral Therapy</i> , 2008, 13, 771-777.	1.0	11
431	Serum soluble transferrin receptor in the diagnosis of iron deficiency in chronic liver disease. <i>International Journal of Laboratory Hematology</i> , 1999, 21, 93-98.	0.2	10
432	Long-Term Follow-Up of Antiretroviral-Naive HIV-Positive Patients Treated With Nevirapine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 26, 462-465.	2.1	10

#	ARTICLE	IF	CITATIONS
433	Changes in AIDS-Defining Illnesses in a London Clinic, 1987-1998. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 2006, 21, 401.	0.3	10
434	Emergence of the H208Y mutation in the reverse transcriptase (RT) of HIV-1 in association with nucleoside RT inhibitor therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 1013-1016.	3.0	10
435	Cervical intraepithelial neoplasia treatment in Human Immunodeficiency Virus-positive women. <i>Journal of Obstetrics and Gynaecology</i> , 2008, 28, 327-332.	0.9	10
436	Developing a multidisciplinary network for clinical research on HIV infection: the EuroCoord experience. <i>Clinical Investigation</i> , 2012, 2, 255-264.	0.0	10
437	Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. <i>BMC Nephrology</i> , 2014, 15, 51.	1.8	10
438	Time to initiation of antiretroviral therapy in HIV-infected patients diagnosed with an opportunistic disease: a cohort study. <i>HIV Medicine</i> , 2015, 16, 219-229.	2.2	10
439	Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals. <i>Aids</i> , 2016, 30, 1583-1596.	2.2	10
440	Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. <i>Lancet HIV</i> , 2017, 4, e251-e259.	4.7	10
441	An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2075-2082.	3.0	10
442	Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study. <i>Journal of the International AIDS Society</i> , 2018, 21, e25083.	3.0	10
443	Patients' perspectives on the development of HIV services to accommodate ageing with HIV: a qualitative study. <i>International Journal of STD and AIDS</i> , 2018, 29, 483-490.	1.1	10
444	Sleep health and cognitive function among people with and without HIV: the use of different machine learning approaches. <i>Sleep</i> , 2021, 44, .	1.1	10
445	Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels compared to protease inhibitor-based therapy. <i>ELife</i> , 2021, 10, .	6.0	10
446	The Effect of HBV Genotype C on the Development of HCC Differs Between Wild-Type Viruses and Those With BCP Double Mutations (T1762A1764). <i>Hepatitis Monthly</i> , 2014, 14, e16214.	0.2	10
447	Genetic Variants of APOL1 Are Major Determinants of Kidney Failure in People of African Ancestry With HIV. <i>Kidney International Reports</i> , 2022, 7, 786-796.	0.8	10
448	Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease. <i>Journal of Internal Medicine</i> , 1998, 244, 515-22.	6.0	10
449	Viral burden in HIV infection. <i>Nature</i> , 1994, 367, 124-124.	27.8	9
450	Changing treatment patterns among patients with HIV: Royal Free Hospital 1987-97. <i>HIV Medicine</i> , 1999, 1, 32-39.	2.2	9

#	ARTICLE	IF	CITATIONS
451	The Changing Pattern of Bronchoscopy in an HIV-Infected Population. <i>Chest</i> , 2002, 122, 878-885.	0.8	9
452	The epidemiology of genital infection with herpes simplex virus types 1 and 2 in genitourinary medicine attendees in inner London. <i>Sexually Transmitted Infections</i> , 2005, 81, 306-308.	1.9	9
453	Magnitude and Determinants of CD4 Recovery After HAART Resumption After 1 Cycle of Treatment Interruption. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 588-594.	2.1	9
454	Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance. <i>BMC Medical Research Methodology</i> , 2012, 12, 30.	3.1	9
455	Laboratory adverse events and discontinuation of therapy according to CD4+ cell count at the start of antiretroviral therapy. <i>Aids</i> , 2014, 28, 1333-1339.	2.2	9
456	Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression. <i>Aids</i> , 2014, 28, 919-924.	2.2	9
457	Use of Surveillance Data on HIV Diagnoses with HIV-Related Symptoms to Estimate the Number of People Living with Undiagnosed HIV in Need of Antiretroviral Therapy. <i>PLoS ONE</i> , 2015, 10, e0121992.	2.5	9
458	Prevalence of diagnosed HIV infection among persons with hepatitis C virus infection: England, 2008-2014. <i>HIV Medicine</i> , 2018, 19, 708-715.	2.2	9
459	Assessment of trabecular bone score, an index of bone microarchitecture, in HIV positive and HIV negative persons within the HIV UPBEAT cohort. <i>PLoS ONE</i> , 2019, 14, e0213440.	2.5	9
460	The predictors of pain extent in people living with HIV. <i>Aids</i> , 2020, 34, 2071-2079.	2.2	9
461	Antiretroviral treatment outcomes among late HIV presenters initiating treatment with integrase inhibitors or protease inhibitors. <i>HIV Medicine</i> , 2021, 22, 47-53.	2.2	9
462	Mortality and AIDS-defining events among young people following transition from paediatric to adult HIV care in the UK. <i>HIV Medicine</i> , 2021, 22, 631-640.	2.2	9
463	Serum Î2-Microglobulin at HIV-1 Seroconversion As a Predictor of Severe Immunodeficiency During 10 Years of Followup. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1996, 13, 262-266.	0.3	9
464	Comparison of immunodeficiency and AIDS defining conditions in HIV negative and HIV positive men with haemophilia A. <i>BMJ: British Medical Journal</i> , 1996, 312, 207-210.	2.3	9
465	High cost, low volume care: the case of haemophilia. <i>BMJ: British Medical Journal</i> , 1997, 315, 962-963.	2.3	9
466	The menopause transition in women living with HIV: current evidence and future avenues of research. <i>Journal of Virus Eradication</i> , 2016, 2, 114-6.	0.5	9
467	Correlation between cerebrospinal fluid and plasma neurofilament light protein in treated HIV infection: results from the COBRA study. <i>Journal of NeuroVirology</i> , 2022, 28, 54-63.	2.1	9
468	Definition of loss of virological response in trials of antiretroviral drugs. <i>Aids</i> , 2003, 17, 1997-1998.	2.2	8

#	ARTICLE	IF	CITATIONS
469	Impact of the Insect Biting Nuisance on a British Youth Expedition to Alaska. <i>Journal of Travel Medicine</i> , 2006, 9, 76-81.	3.0	8
470	Towards a better liver transplant allocation system. <i>Liver Transplantation</i> , 2007, 13, 935-936.	2.4	8
471	Virological Response to Initial Antiretroviral Regimens Containing Abacavir or Tenofovir. <i>Journal of Infectious Diseases</i> , 2009, 200, 710-714.	4.0	8
472	The impact of HIV drug resistance testing on changes to treatment. <i>Aids</i> , 2011, 25, 603-610.	2.2	8
473	Laboratory diagnosis of von Willebrand disease: results from a prospective and blind study in 32 laboratories worldwide using lyophilized plasmas. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 220-222.	3.8	8
474	Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals. <i>Aids</i> , 2012, 26, 1707-1717.	2.2	8
475	Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy. <i>Aids</i> , 2015, 29, 801-809.	2.2	8
476	Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?. <i>Aids</i> , 2016, 30, 1629-1637.	2.2	8
477	Cirrhosis and liver transplantation in patients co-infected with HIV and hepatitis B or C: an observational cohort study. <i>Infection</i> , 2017, 45, 215-220.	4.7	8
478	Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. <i>Journal of Infectious Diseases</i> , 2019, 220, 1629-1634.	4.0	8
479	Cognitive function, depressive symptoms and syphilis in HIV-positive and HIV-negative individuals. <i>International Journal of STD and AIDS</i> , 2019, 30, 440-446.	1.1	8
480	High-risk behaviours, and their associations with mental health, adherence to antiretroviral therapy and HIV parameters, in HIV-positive men who have sex with men. <i>HIV Medicine</i> , 2019, 20, 131-136.	2.2	8
481	Incidence of and risk factors for tuberculosis among people with HIV on antiretroviral therapy in the United Kingdom. <i>Aids</i> , 2020, 34, 1813-1821.	2.2	8
482	HEPCARE EUROPE- A case study of a service innovation project aiming at improving the elimination of HCV in vulnerable populations in four European cities. <i>International Journal of Infectious Diseases</i> , 2020, 101, 374-379.	3.3	8
483	Factors associated with obesity in the Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) cohort: an observational cross-sectional analysis. <i>HIV Medicine</i> , 2020, 21, 441-452.	2.2	8
484	Differences in HIV clinical outcomes amongst heterosexuals in the United Kingdom by ethnicity. <i>Aids</i> , 2021, 35, 1813-1821.	2.2	8
485	No need for secondary <i>Pneumocystis jirovecii</i> pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/μL. <i>Journal of the International AIDS Society</i> , 2021, 24, e25726.	3.0	8
486	Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, .	3.0	8

#	ARTICLE	IF	CITATIONS
487	Hepatitis C Virus and HIV Coinfection. <i>AIDS Patient Care and STDs</i> , 1998, 12, 199-207.	2.5	7
488	Assessing the impact of highly active antiretroviral therapy on AIDS and death. <i>Aids</i> , 1999, 13, 2165-2166.	2.2	7
489	Relationships among the Detection of p24 Antigen, Human Immunodeficiency Virus (HIV) RNA Level, CD4 Cell Count, and Disease Progression in HIV-Infected Individuals with Hemophilia. <i>Journal of Infectious Diseases</i> , 2001, 184, 511-514.	4.0	7
490	Pre-travel preparation and outcome of HIV-infected travellers from a UK clinic. <i>Travel Medicine and Infectious Disease</i> , 2003, 1, 114-118.	3.0	7
491	HIV Viremia and the Development of AIDS-Related Lymphoma in Patients Treated with Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2009, 200, 8-10.	4.0	7
492	HIV-Infected Late Presenter Patients. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-2.	0.7	7
493	Using two on-going HIV studies to obtain clinical data from before, during and after pregnancy for HIV-positive women. <i>BMC Medical Research Methodology</i> , 2012, 12, 110.	3.1	7
494	Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. <i>HIV Medicine</i> , 2013, 14, 571-577.	2.2	7
495	Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children – a EuroCoord-CHAIN-EPPICC joint project. <i>BMC Infectious Diseases</i> , 2016, 16, 654.	2.9	7
496	Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation. <i>HIV Medicine</i> , 2016, 17, 368-372.	2.2	7
497	Measurement of Retinal Vessels as a Biomarker of Cerebrovascular Aging in Older HIV-Positive Men Compared With Controls. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 199-205.	2.1	7
498	HIV coinfection among persons diagnosed with hepatitis B in England in 2008–2014. <i>HIV Medicine</i> , 2019, 20, 255-263.	2.2	7
499	Serious clinical events in HIV-positive persons with chronic kidney disease. <i>Aids</i> , 2019, 33, 2173-2188.	2.2	7
500	Respiratory symptoms and chronic bronchitis in people with and without HIV infection. <i>HIV Medicine</i> , 2021, 22, 11-21.	2.2	7
501	The association between use of chemsex drugs and HIV clinic attendance among gay and bisexual men living with HIV in London. <i>HIV Medicine</i> , 2021, 22, 641-649.	2.2	7
502	Cofactors and markers of disease progression in human immunodeficiency virus infection. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 1998, 161, 177-189.	1.1	6
503	The effect of highly active antiretroviral therapy for HIV on the anti-HCV specific humoral immune response. <i>Journal of Medical Virology</i> , 2004, 72, 187-193.	5.0	6
504	Medical student attitudes towards HIV. <i>International Journal of STD and AIDS</i> , 2006, 17, 513-516.	1.1	6

#	ARTICLE	IF	CITATIONS
505	Boosted Lopinavirâ€“ Versus Boosted Atazanavirâ€“Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. <i>Clinical Infectious Diseases</i> , 2015, 60, 1262-1268.	5.8	6
506	Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz+â€“tenofovir+â€“emtricitabine for HIV. <i>Journal of Virus Eradication</i> , 2019, 5, 204-211.	0.5	6
507	Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 314-320.	2.1	6
508	The Impact of Immunosuppression on Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: The D:A:D Study. <i>Journal of Infectious Diseases</i> , 2021, 223, 632-637.	4.0	6
509	A long-term follow-up of hepatitis B vaccination in patients with congenital clotting disorders. <i>Vaccine</i> , 1994, 12, 978-983.	3.8	5
510	The role of observational studies in assessing the impact of antiviral therapies. <i>Current Opinion in Infectious Diseases</i> , 2000, 13, 631-635.	3.1	5
511	Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infection. <i>Aids</i> , 2003, 17, 1009-1016.	2.2	5
512	South Asians with HIV in London: is it time to rethink sexual health service delivery to meet the needs of heterosexual ethnic minorities?. <i>Sexually Transmitted Infections</i> , 2004, 80, 75-a-76.	1.9	5
513	Twenty five years of HIV infection in haemophilic men in Britain: an observational study. <i>BMJ: British Medical Journal</i> , 2005, 331, 997-998.	2.3	5
514	An audit of viral load in one clinical population to describe features of viraemic patients on antiretroviral therapy. <i>HIV Medicine</i> , 2008, 9, 208-213.	2.2	5
515	Cohort studies: to what extent can they inform treatment guidelines?. <i>Current Opinion in Infectious Diseases</i> , 2010, 23, 15-20.	3.1	5
516	Does Discordancy Between the CD4 Count and CD4 Percentage in HIV-Positive Individuals Influence Outcomes on Highly Active Antiretroviral Therapy?. <i>Journal of Infectious Diseases</i> , 2012, 205, 540-547.	4.0	5
517	Determining the Origins of Human Immunodeficiency Virus Type 1 Drug-resistant Minority Variants in People Who Are Recently Infected Using Phylogenetic Reconstruction. <i>Clinical Infectious Diseases</i> , 2018, 69, 1136-1143.	5.8	5
518	CD4+:CD8+ T Cell Ratio Normalization and the Development of AIDS Events in People with HIV Starting Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 808-816.	1.1	5
519	Treatment of mild-to-moderate pelvic inflammatory disease with a short-course azithromycin-based regimen versus ofloxacin plus metronidazole: results of a multicentre, randomised controlled trial. <i>Sexually Transmitted Infections</i> , 2021, 97, 177-182.	1.9	5
520	Costâ€“effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States. <i>Journal of the International AIDS Society</i> , 2021, 24, e25690.	3.0	5
521	The Global Task Force for Chronic Pain in People with HIV (PWH): Developing a research agenda in an emerging field. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2023, 35, 1215-1223.	1.2	5
522	Menopausal status, age and management among women living with HIV in the UK. <i>HIV Medicine</i> , 2021, 22, 834-842.	2.2	5

#	ARTICLE	IF	CITATIONS
523	Cardiovascular risks associated with protease inhibitors for the treatment of HIV. Expert Opinion on Drug Safety, 2021, 20, 1351-1366.	2.4	5
524	Quantity of cytomegalovirus viraemia is a major risk factor for cytomegalovirus disease after renal transplantation. Journal of Medical Virology, 1997, 52, 200-205.	5.0	5
525	Can Linear Regression Modeling Help Clinicians in the Interpretation of Genotypic Resistance Data? An Application to Derive a Lopinavir-Score. PLoS ONE, 2011, 6, e25665.	2.5	5
526	CD4 ⁺ :CD8 ⁺ T-cell Ratio Changes in People with HIV Receiving Antiretroviral Treatment. Antiviral Therapy, 2020, 25, 91-100.	1.0	5
527	Follicle-stimulating hormone in postmenopausal women living with HIV: a prevalence study. HIV Medicine, 2022, 23, 434-440.	2.2	5
528	Obesity in women living with HIV aged 45-60 in England: An analysis of the PRIME study. HIV Medicine, 2022, 23, 371-377.	2.2	5
529	Active drug injecting and progression of HIV infection. Aids, 1994, 8, 385-386.	2.2	4
530	Investigating temporal changes in the rate of HIV progression. Aids, 1997, 11, 1647-1649.	2.2	4
531	Survival after a very low (< 5 Å— 106/l) CD4+ T-cell count in individuals infected with HIV. Aids, 1997, 11, 1123-1127.	2.2	4
532	Long-term patterns of hepatitis C virus RNA concentrations in a cohort of HIV seronegative men with bleeding disorders. Journal of Medical Virology, 2002, 68, 68-75.	5.0	4
533	The seroepidemiology of HTLV-I amongst genitourinary medicine (GUM) attendees in South East London. Journal of Clinical Virology, 2008, 43, 253-254.	3.1	4
534	Early antiretroviral therapy: the role of cohorts. Current Opinion in HIV and AIDS, 2009, 4, 200-205.	3.8	4
535	Is 1 Alanine Transaminase >200 IU Enough to Define an Alanine Transaminase Flare in HIV-Infected Populations? A New Definition Derived From a Large Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, 391-396.	2.1	4
536	Early initiation of treatment for HIV infection. Lancet, The, 2010, 375, 639.	13.7	4
537	Non-uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells/µL in the UK. HIV Medicine, 2012, 13, 73-78.	2.2	4
538	Aspartate Aminotransferase-to-Platelet Ratio Index Is a Powerful Predictor of Mortality Among HIV-Positive Patients. Journal of Infectious Diseases, 2013, 207, 367-368.	4.0	4
539	Understanding HIV-positive patients' preferences for healthcare services: a protocol for a discrete choice experiment. BMJ Open, 2016, 6, e008549.	1.9	4
540	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. Journal of Antimicrobial Chemotherapy, 2016, 71, 1352-1360.	3.0	4

#	ARTICLE	IF	CITATIONS
541	A tale of two countries: all-cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada. <i>HIV Medicine</i> , 2017, 18, 655-666.	2.2	4
542	Benchmarked performance charts using principal components analysis to improve the effectiveness of feedback for audit data in HIV care. <i>BMC Health Services Research</i> , 2017, 17, 506.	2.2	4
543	Associations between serum albumin and serious non-AIDS events among people living with HIV. <i>Aids</i> , 2018, 32, 1837-1848.	2.2	4
544	Protocol of a two arm randomised, multi-centre, 12-month controlled trial: evaluating the impact of a Cognitive Behavioural Therapy (CBT)-based intervention Supporting Uptake and Adherence to antiretrovirals (SUPA) in adults with HIV. <i>BMC Public Health</i> , 2019, 19, 905.	2.9	4
545	Monocyte and T Cell Immune Phenotypic Profiles Associated With Age Advancement Differ Between People With HIV, Lifestyle-Comparable Controls and Blood Donors. <i>Frontiers in Immunology</i> , 2020, 11, 581616.	4.8	4
546	Monitoring of older HIV-positive adults by HIV clinics in the United Kingdom: a national quality improvement initiative. <i>HIV Medicine</i> , 2020, 21, 409-417.	2.2	4
547	Differences in presentation and follow-up between HIV-1 antibody positive teenagers and adults. <i>Aids</i> , 2003, 17, 260-262.	2.2	4
548	Clinical research cerebral MRI findings in HIV-positive subjects and appropriate controls. <i>Aids</i> , 2018, 32, 2077-2081.	2.2	4
549	Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz+tenofovir+emtricitabine for HIV. <i>Journal of Virus Eradication</i> , 2019, 5, 204-211.	0.5	4
550	Sickle Cell Trait and Kidney Disease in People of African Ancestry With HIV. <i>Kidney International Reports</i> , 2022, 7, 465-473.	0.8	4
551	Assessing the relationship between productivity levels and severity of haemophilia. <i>Haemophilia</i> , 2001, 7, 459-463.	2.1	3
552	Cohort studies in sexual health. <i>Sexually Transmitted Infections</i> , 2001, 77, 174-178.	1.9	3
553	Sociodemography of genital co-infection with <i>Neisseria gonorrhoeae</i> and <i>Chlamydia trachomatis</i> in Coventry, UK. <i>International Journal of STD and AIDS</i> , 2005, 16, 318-322.	1.1	3
554	Providing written information on HIV testing improves patient knowledge but does not affect test uptake. <i>International Journal of STD and AIDS</i> , 2006, 17, 185-188.	1.1	3
555	Treatment outcomes amongst previously antiretroviral-naïve HIV-infected patients starting lopinavir/ritonavir-containing antiretroviral regimens at the Royal Free Hospital*. <i>HIV Medicine</i> , 2007, 8, 55-63.	2.2	3
556	Assessment of hospitalizations among HIV patients in the UK: a national cross-sectional survey. <i>International Journal of STD and AIDS</i> , 2010, 21, 752-754.	1.1	3
557	HIV-1 Subtype and Virological Response to Antiretroviral Therapy: A Confirmatory Analysis. <i>Clinical Infectious Diseases</i> , 2013, 56, 162-163.	5.8	3
558	Clinical and epidemiological characteristics of patients with early syphilis from three academic centres in Poland, Germany and Ireland: initial findings from the POETS study. <i>Sexually Transmitted Infections</i> , 2015, 91, 389-394.	1.9	3

#	ARTICLE	IF	CITATIONS
559	Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes. <i>Medicine (United States)</i> , 2016, 95, e5133.	1.0	3
560	The Association between Detected drug Resistance Mutations and CD4 ⁺ T-Cell Decline in HIV-Positive Individuals Maintained on a Failing Treatment Regimen. <i>Antiviral Therapy</i> , 2018, 23, 105-116.	1.0	3
561	Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data. <i>AIDS Research and Therapy</i> , 2018, 15, 11.	1.7	3
562	Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation. <i>HIV Medicine</i> , 2020, 21, 309-321.	2.2	3
563	Can we have failed to separate my HIV from this pain? the challenge of managing chronic pain among people with HIV. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, , 1-9.	1.2	3
564	Prevalence of pain in women living with HIV aged 45-60: associated factors and impact on patient-reported outcomes. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, , 1-10.	1.2	3
565	Associations between plasma nucleoside reverse transcriptase inhibitors concentrations and cognitive function in people with HIV. <i>PLoS ONE</i> , 2021, 16, e0253861.	2.5	3
566	Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease. <i>Journal of Internal Medicine</i> , 1998, 244, 515-522.	6.0	3
567	Relation Between Soluble CD30 Levels Measured Soon After HIV Seroconversion and Disease Progression in Men With Hemophilia. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997, 16, 279-283.	0.3	3
568	Association between health-related quality of life and menopausal status and symptoms in women living with HIV aged 45-60 years in England: An analysis of the PRIME study. <i>Women's Health</i> , 2022, 18, 174550652110687.	1.5	3
569	Re-evaluation of annual cytology using HPV self-sampling to upgrade prevention (REACH UP): A feasibility study in women living with HIV in the UK. <i>HIV Medicine</i> , 2022, 23, 390-396.	2.2	3
570	The Problems Faced When Assessing the Prevalence and Incidence of Antiretroviral-Related Toxicities. <i>Antiviral Therapy</i> , 2004, 9, 865-878.	1.0	3
571	Are there two types of response to HIV?. <i>Lancet, The</i> , 1993, 341, 1023-1024.	13.7	2
572	The Use of Backcalculation to Estimate the Prevalence of Severe Immunodeficiency Induced by Human Immunodeficiency Virus in England and Wales. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 1994, 157, 41.	1.1	2
573	Prophylaxis for <i>Pneumocystis carinii</i> pneumonia: its impact on the natural history of HIV infection in men with haemophilia. <i>Haemophilia</i> , 1995, 1, 37-44.	2.1	2
574	Evaluating the effect of year of seroconversion on HIV progression in cohort studies. <i>Aids</i> , 1998, 12, 1353-1360.	2.2	2
575	The effects of the 32bp CCR5 deletion on HIV transmission and HIV disease progression in individuals with haemophilia. <i>British Journal of Haematology</i> , 2000, 111, 136-142.	2.5	2
576	O422 Do the disadvantages of late initiation of HAART persist in patients achieving and maintaining viral load (VL) suppression for a year on HAART?. <i>Journal of the International AIDS Society</i> , 2008, 11, O44.	3.0	2

#	ARTICLE	IF	CITATIONS
577	The incidence of HIV-related disease in a cohort of haemophilic men: natural history and changes since the introduction of pre-AIDS treatment. <i>International Journal of Laboratory Hematology</i> , 2008, 15, 241-251.	0.2	2
578	CD4 lymphocyte count as predictor of drug expenditure in a cohort of anti-HIV seropositive haemophiliacs. <i>International Journal of Pharmacy Practice</i> , 2011, 1, 210-211.	0.6	2
579	Superior neurocognitive function is associated with central nervous system antiretroviral drug penetration only in regimens containing more than three antiretroviral agents. <i>Aids</i> , 2011, 25, 1014-1015.	2.2	2
580	Response to antiretroviral therapy (ART): comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with ART naïve women. <i>BMC Infectious Diseases</i> , 2014, 14, 127.	2.9	2
581	Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 102-109.	2.1	2
582	Associations of menopausal age with virological outcomes and engagement in care among women living with HIV in the UK. <i>HIV Research and Clinical Practice</i> , 2020, 21, 174-181.	1.1	2
583	Impact of Kaposi's sarcoma on HIV disease progression. <i>Aids</i> , 1999, 13, 286.	2.2	2
584	Response: Arguments contradict the "foreign protein-zidovudine" hypothesis. <i>BMJ: British Medical Journal</i> , 1996, 312, 211-212.	2.3	2
585	Late diagnosis of human immunodeficiency virus infection is linked to higher rates of epilepsy in children in the Eastern Cape of South Africa. <i>Southern African Journal of HIV Medicine</i> , 2020, 21, 1047.	0.9	2
586	The Prevalence and Patterns of Menopausal Symptoms in Women Living with HIV. <i>AIDS and Behavior</i> , 2022, 26, 3679-3687.	2.7	2
587	The use of CD4 counts as prognostic markers in HIV infection. <i>Aids</i> , 1995, 9, 1205-1206.	2.2	1
588	The use of intermediate-purity clotting factor concentrates and HIV disease progression in men with haemophilia. <i>Haemophilia</i> , 1996, 2, 78-81.	2.1	1
589	Changes in Lymphocyte Subsets in Human Immunodeficiency Virus-Positive Persons with ≥ 5 CD4 T Lymphocytes/mm ³ . <i>Journal of Infectious Diseases</i> , 1998, 178, 1166-1169.	4.0	1
590	Family issues in HIV-infected haemophilic patients. <i>Aids</i> , 1999, 13, 2314.	2.2	1
591	Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population. <i>HIV Medicine</i> , 2004, 5, 314-314.	2.2	1
592	Analyse transplant outcomes in distinct epochs of follow-up – Authors' reply. <i>Lancet, The</i> , 2006, 367, 1816-1817.	18.7	1
593	A Survey of the Profile and Perceived Value of a London Travel Clinic. <i>Journal of Travel Medicine</i> , 2000, 7, 330-332.	3.0	1
594	Cardiovascular risk and choice of HIV drug regimen. <i>Future HIV Therapy</i> , 2008, 2, 83-92.	0.4	1

#	ARTICLE	IF	CITATIONS
595	Impact on life expectancy of late diagnosis and treatment of HIV-1 infected individuals: UK CHIC. <i>Journal of the International AIDS Society</i> , 2010, 13, O27-O27.	3.0	1
596	Predictors of the change in bilirubin levels over twelve weeks of treatment with atazanavir. <i>AIDS Research and Therapy</i> , 2013, 10, 13.	1.7	1
597	Cognitive function and drivers of cognitive impairment in a European and a Korean cohort of people living with HIV. <i>International Journal of STD and AIDS</i> , 2020, 31, 30-37.	1.1	1
598	Cross-Sectional Studies in AIDS Pathogenesis. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997, 14, 153-157.	0.3	1
599	When should antiretroviral therapy be started in HIV-positive persons?. <i>F1000 Medicine Reports</i> , 2010, 2, 81.	2.9	1
600	Correlation between computerised and standard cognitive testing in people with HIV and HIV-negative individuals. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 1296-1307.	1.2	1
601	Association of pregnancy with engagement in HIV care among women with HIV in the UK: a cohort study. <i>Lancet HIV</i> , 2021, 8, e747-e754.	4.7	1
602	Patterns of mental health symptoms among women living with HIV ages 45-60 in England: associations with demographic and clinical factors. <i>Menopause</i> , 2022, 29, 421-429.	2.0	1
603	New AIDS definition. <i>Lancet, The</i> , 1993, 341, 178.	13.7	0
604	HIV follow-up care at a London teaching hospital. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 1998, 10, 165-173.	1.2	0
605	Viral-load kinetics and CMV disease. <i>Lancet, The</i> , 2000, 356, 1353.	13.7	0
606	Early assessment of anti-HIV drug efficacy. <i>Lancet, The</i> , 2002, 359, 1696-1697.	13.7	0
607	Reply to Boyd and Bothamley and to Franzetti et al. <i>Clinical Infectious Diseases</i> , 2006, 42, 1499-1500.	5.8	0
608	Authors' response to Drs Scourfield, Jackson and Nelson. <i>HIV Medicine</i> , 2011, 12, 450-451.	2.2	0
609	Does antiretroviral therapy started at high CD4 cell counts reduce an individual HIV-positive patient's disease risk?. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 1-3.	3.8	0
610	HIV - the good news. <i>Trends in Urology & Men's Health</i> , 2018, 9, 21-24.	0.4	0
611	CD4 Counts as Surrogate Markers for Progression to AIDS. <i>Annals of Internal Medicine</i> , 1994, 120, 87.	3.9	0
612	Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients. <i>Antiviral Therapy</i> , 2003, 8, 301-8.	1.0	0

#	ARTICLE	IF	CITATIONS
613	Special issue on Women and HIV to mark International Women’s Day. HIV Medicine, 2022, 23, 309-309.	2.2	0
614	Associations with sub-optimal clinic attendance and reasons for missed appointments among heterosexual women and men living with HIV in London. AIDS and Behavior, 2022, , .	2.7	0
615	Drug Resistance Genotypes Predict Response to Amprenavir-Containing Regimens in Highly Drug-Experienced HIV-1-Infected Patients. Antiviral Therapy, 2003, 8, 301-308.	1.0	0